鼻腔给药可提高具有首过效应药物的生物利用度。通常认为,它可使药物透过血脑屏障进入脑内。化合物I[3,3-双(4-吡啶甲基)1-苯基吲哚啉-2-酮]正开发为记忆增强药,其作用靶器官是脑组织。口服具有首过效应。本文研究鼻腔给药后能否增加I的脑内释放及提高其生物利用度。生物利用度研究,雄性大鼠麻醉后,分别以口服、静注和鼻腔三种方式给药。I·2 HCl Nasal administration increases the bioavailability of drugs with first pass effects. It is generally believed that it allows the drug to penetrate the blood-brain barrier into the brain. Compound I [3,3-bis (4-picolyl) 1-phenylindolin-2-one] is being developed as a memory-enhancing drug whose target organ is brain tissue. Oral has the first pass effect. This article investigates whether intrathecal release of I and its bioavailability increase after nasal administration. Bioavailability studies, male rats after anesthesia, respectively, oral, intravenous and nasal administration of three ways. I · 2 HCl